NasdaqCM:ORGOBiotechs
Organogenesis Holdings (ORGO) Q4 EPS Rebound Tests Bullish Earnings Ramp Narrative
Organogenesis Holdings (ORGO) closed FY 2025 with fourth quarter revenue of US$225.6 million and basic EPS of US$0.28, alongside net income of US$35.1 million that capped a profitable trailing twelve month period. The company has seen quarterly revenue move from US$126.7 million and EPS of US$0.05 in Q4 2024 to US$225.6 million and EPS of US$0.28 in Q4 2025. Trailing twelve month EPS shifted from roughly flat at US$0.01 in Q4 2024 to US$0.16 in Q4 2025, setting up a results season where the...